Skip to main content

Market Overview

Hoth Therapeutics' HT-003 Shows Encouraging Action Against Acne In Animal Model

Share:
Hoth Therapeutics' HT-003 Shows Encouraging Action Against Acne In Animal Model
  • Hoth Therapeutics Inc (NASDAQ: HOTH) has announced that its HT-003 group of assets has yielded positive results in an in vivo acne therapeutic model
  • The model showed that HT-003 reduces toll-like receptor 2 (TLR2) expression, one of the most critical pathways for acne pathophysiology. 
  • The study also showed that HT-003 reduces the expression of numerous cytokines critical for acne pathophysiology that are also relevant therapeutic markers for other inflammatory-driven skin diseases.
  • HT-003 is a group of retinoic acid metabolism blocking agents, novel agents that prevent the breakdown of retinoic acid. Retinoic acid acts as an anti-inflammatory agent in the body.
  • In addition to the dermatologic application, Hoth Therapeutics is exploring the potential application of HT-003 assets in inflammatory bowel disorders.
  • Price Action: HOTH shares are down 2.01% at $1.46 during the market session on the last check Tuesday.
 

Related Articles (HOTH)

View Comments and Join the Discussion!

Posted-In: BriefsBiotech News Penny Stocks Health Care General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com